MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
1.265
-0.135 (-9.64%)
At close: Nov 20, 2024, 4:00 PM
1.270
+0.005 (0.40%)
Pre-market: Nov 21, 2024, 7:04 AM EST
MIRA Pharmaceuticals Employees
The last reported number of employees for MIRA Pharmaceuticals was 3.
Employees
3
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,746,780
Market Cap
20.95M
No historical employees data available.
Related Stocks
| Company Name | Employees |
|---|---|
| BioXcel Therapeutics | 74 |
| Enlivex Therapeutics | 71 |
| PolyPid | 62 |
| NeuroSense Therapeutics | 18 |
| Tempest Therapeutics | 17 |
| AEON Biopharma | 10 |
| Ocean Biomedical | 9 |
| XTL Biopharmaceuticals | 7 |
MIRA News
- 1 day ago - MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site - Accesswire
- 24 days ago - MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - Accesswire
- 4 weeks ago - MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study - Accesswire
- 7 weeks ago - MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 - Accesswire
- 2 months ago - MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - Accesswire
- 2 months ago - MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - Accesswire
- 3 months ago - MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study - Accesswire
- 3 months ago - MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End - Accesswire